Skip to main content
Figure 1 | BMC Medicine

Figure 1

From: Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world

Figure 1

Sensitivity analyses on the base case cost effectiveness ratio ($ per QALY, except in D where € 's *1000 were used) using the CoRoVa model for Afr (A), Sear (B), Amr (D), and Eur (D) regions. Parameters were varied through halving and doubling, except for the discount rates which were 0% and 4% for both costs and health effects. Dark bars show the incremental cost effectiveness ratio after a 100% decrease in the parameter, whereas light bars show the incremental cost effectiveness ratio after a 100% increase (note that an increase in the incidence or the costs resulted in negative cost effectiveness ratios in the Eur region [D]). Note that when the incidence of RVGE was increased or decreased, the total number of deaths was kept constant to identify the sole effect of incidence. QALY, quality adjusted life year; RVGE, rotavirus gastroenteritis.

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us